Home » FDA Licenses Rosetta Resolver System for Use in the CDER
FDA Licenses Rosetta Resolver System for Use in the CDER
PharmaManufacturing.com
08/24/2005
CDER will use the Rosetta Resolver system to better understand, learn from and reproduce analyses conducted by pharmaceutical companies who voluntarily submit genomics data. In addition, they will perform independent analyses using the Rosetta Resolver system's microarray data management and analysis tools.
"As the VGDS program gains momentum, CDER will receive a wide variety and growing volume of gene expression data," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. "The Rosetta Resolver system's robust capacity, ability to analyze and manage varying data formats, and support of industry standards allows it to efficiently accept and manage these data. In addition, Rosetta Biosoftware is committed to work with sponsors and the FDA to simplify and standardize the submission process."
The Rosetta Resolver system is developed and supported by Rosetta Biosoftware, and is distributed exclusively by Agilent Technologies, Inc.
About the Rosetta Resolver System
The Rosetta Resolver system is a high-capacity data storage, retrieval and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles.
The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The system can accept and analyze data from a wide variety of expression profiling formats, including Agilent DNA microarrays, and applies Rosetta Biosoftware's proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com.
More News:
- 03/18/2010 Teva Beats Out Pfizer & Activa in 3.5BN Rationpharm Generics DealFrom CTV.ca
- 03/18/2010 Johnson & Johnson CEO Weldon Gets 11% 2009 Raise, to $25.6MFrom AP.com
- 03/17/2010 $75 Million Drug Heist is Bitter Pill for LillyFrom IndyStar.com
- 03/17/2010 R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
- 03/15/2010 Diabetes Drug From Lilly, Amylin Under ScrutinyFrom Forbes.com
- 03/12/2010 AstraZeneca Inks First Generic Drugs DealFrom Business.timesonline.co.uk
- 03/12/2010 AstraZeneca Job Cuts Reflect New Landscape For Drug InnovationFrom FT.com
- 03/10/2010 Novartis Goes Wireless for Process and Plant Info
- 03/10/2010 Concerns Raised about Tromethamine ContaminationFrom Rx-360
- 03/09/2010 Pittcon 2010: Thermo Fisher Scientific Continues in Growth Mode
- All news »
More content on this topic:
Get Connected Now!
- Featured White Papers

Print page